1 Introduction Allogeneic hematopoietic cell transplantation (alloHCT) cures high-risk hematologic disease, but posttransplant outcomes remain highly variable and nonrelapse mortality (NRM) continues to limit benefit, even among patients with similar disease characteristics [1].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ivan Pasic
HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study
Keywords Frailty syndrome HCT frailty scale Allogeneic-HCT Pre-habilitation Survival Supportive care Real-world data Evidence before this study We searched PubMed, Embase, and Web of Science from database inception to Dec 1, 2024, using the terms “frailty”, “geriatric assessment”, “hematopoietic cell transplantation”, “allogeneic transplant”, and “HCT frailty scale”, limited to English and Spanish language publications.
Prolonged length of stay in high-risk patients undergoing allogeneic stem cell transplantation: a call to action for addressing healthcare challenges - Bone Marrow Transplantation
Abstract Allogeneic hematopoietic stem-cell transplantation (allo-HCT) is a potentially curative treatment for hematological diseases, but the prolonged length of stay (LOS) post-transplant remains a significant challenge. This retrospective cohort study analyzed 977 patients undergoing allo-HCT at Princess Margaret Cancer Centre between 2017 and 2022 to identify predictors of prolonged LOS and their impact on overall survival (OS) and non-relapse mortality (NRM).
Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience
CONFLICT OF INTEREST STATEMENT The authors have no conflict of interest to declare. REFERENCES 1, , , et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2014; 59(4): 473-481. 2, . Cytomegalovirus infection in the bone marrow transplant recipient. Infect Dis Clin N Am. 1995; 9(4): 879-900. 3, , , , , .
Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies | Bone Marrow Transplantation
Abstract The ideal immunosuppressive agents to complement post-transplant cyclophosphamide (PTCy) in PBSC-based haploidentical hematopoietic cell transplantation (haplo-HCT) remain debated. This study looks at our experience with ATG-PTCy-Cyclosporine (CsA) prophylaxis in PB haplo-HCT since 2015. Between October 2015 and December 2021, 157 adults underwent haploidentical hematopoietic cell transplantation (haplo-HCT) using a GVHD prophylaxis regimen comprising rabbit-ATG, PTCy, and CsA.
Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
HCT frailty scale for younger and older adults undergoing allogeneic hematopoietic cell transplantation - Bone Marrow Transplantation
Abstract The HCT Frailty Scale is an easy prognostic tool composed of (a) Clinical Frailty Scale; (b) Instrumental Activities of Daily Living; (c) Timed-up-and-Go test; (d) Grip Strength; (e) Self-Health Rated Questionnaire; (f) Falls tests; (g) Albumin and C-reactive protein levels. This scale was designed to classify allogeneic hematopoietic cell transplant (alloHCT) candidates into fit, pre-frail and frail groups, irrespective of age.
Tumour lysis syndrome
Practice Open Access CMAJ 195 (14) E515; DOI: https://doi.org/10.1503/cmaj.221433 Tumour lysis syndrome (TLS) is an emergency Tumour lysis syndrome is caused by a rapid breakdown of malignant cells releasing cellular contents into the blood.1 Most often, TLS occurs early after the start of chemotherapy, although it can spontaneously occur before treatment, or with radiation, steroid or targeted treatments in children and adults.1,2 Mortality may be as high as 20%.3–5 Patients with...
Impact of hematopoietic cell transplant frailty scale on transplant outcome in adults - Bone Marrow Transplantation
Abstract This prospective study designs an HCT Frailty Scale to classify alloHCT candidates into groups of frail, pre-frail, and fit, and to be implemented in the first consultation at no additional cost. The present scale is composed of the following eight variables: Clinical Frailty Scale, Instrumental Activities of Daily Living, Timed Up and Go Test, Grip Strength, Self-Health Rated, Falls, Albumin, and C-Reactive Protein.
Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Therapy‐Related Hematologic Malignancies Developing After Multiple Myeloma.
ORIGINAL ARTICLE Ram Vasudevan Nampoothiri, Ram Vasudevan Nampoothiri Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Center, University of Toronto, Toronto Search for more papers by this author Ivan Pasic, Ivan Pasic orcid.org/0000-0001-7595-0113 Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Center, University of Toronto, Toronto Search for more papers by this author Arjun Datt Law, Arjun Datt Law Hans...
ATG and Post‐transplant Cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts
ORIGINAL ARTICLE Igor Novitzky-Basso, Corresponding Author igor.novitzkybasso@uhn.ca orcid.org/0000-0003-3748-3117 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada University of Toronto, Toronto, Canada Corresponding author: Igor Novitzky-Basso MD, PhD, Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Phone: +1 437-986-1828, Fax: +1...
Refined hepatic grading system in chronic graft‐versus‐host disease improves prognostic risk stratification of long‐term outcomes
ORIGINAL ARTICLE Dennis Dong Hwan Kim Corresponding Author dr.dennis.kim@uhn.ca Department of Medical Oncology and Hematology, Hans Messner Allogeneic Stem Cell Transplant Program, Princess Margaret Cancer Centre, Toronto, ON, Canada Correspondence Dennis Dong Hwan Kim, Hans Messner Allogeneic Stem Cell Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, 610 University Ave., Toronto, ON M5G2M9, Canada.
Influence of FLT3‐ITD and NPM1 Status on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Cytogenetically Normal AML
The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Original Article Influence of FLT3‐ITD and NPM1 Status on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Cytogenetically Normal AML Fotios V.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ivan
Contact Ivan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack